Summary of change in circulating T-cell populations between mCRPC and metastatic melanoma patients
| Population | Count ratio of mCRPC (n=13) | Count ratio of melanoma (n=21) | P value |
| CD4+ | 1.17 (0.31, 2.26) | 1.67 (0.90, 3.10) | 0.0057 |
| CD8+ | 1.02 (0.25, 2.34) | 1.53 (0.64, 3.53) | 0.0233 |
| Total CD3+ | 1.16 (0.29, 1.82) | 1.59 (0.90, 3.17) | 0.0057 |
| CD3+CD25+ | 1.26 (0.24, 2.55) | 1.59 (0.80, 4.13) | 0.0764 |
| CD3+CD69+ | 0.84 (0.10, 3.79) | 1.52 (0.34, 20.33) | 0.0256 |
| CD3+CD127+ | 1.08 (0.29, 1.61) | 1.49 (0.87, 3.41) | 0.0046 |
| CD3+PD1+ | 1.45 (0.28, 6.75) | 1.84 (1.16, 6.16) | 0.0131 |
| Total CD3+CD25+CD69+CD127+PD1− | 0.60 (0.05, 2.37) | 1.02 (0.32, 49.34) | 0.0335 |
| Total CD3+CD25+CD69+CD127+PD1+ | 0.87 (0.09, 6.97) | 2.06 (0.41, 9.08) | 0.0131 |
| Total CD3+CD25+CD69+CD127+PD1− | 0.98 (0.10, 2.72) | 1.55 (0.28, 34.18) | 0.0472 |
| Total CD3 +CD25+CD69−CD127+PD1+ | 1.50 (0.33, 5.54) | 2.00 (0.98, 11.15) | 0.0472 |
Count ratio was calculated as the count of each population at on-treatment time point divided by the count at baseline. 95% confidence intervals are included in parenthesis. P values was calculated to determine statistical significance between count ratios of mCRPC and melanoma T-cell populations.
p<0.05 denoted in bold.
mCRPC, metastatic castration resistant prostate cancer.